RCC constitutes approximately 90% of all renal malignancies and 2-3% of all malignant tumours in adults. In spite of the improvement in radiologic methods, nearly 30% of the early metastatic RCC patients are incidentally diagnosed. HMGB1 is an extracellular signalling molecule that plays a role both in inflammation and carcinogenesis. Patients who were followed in Medical Oncology Departments of Denizli Government Hospital and Antalya Education and Research Hospital with a histopathological diagnosis of RCC between years 2010-2012 were enrolled in this study. HMGB1 levels were also assessed in a manually performed quantitative sandwich-enzyme-linked immunosorbent assay (ELISA) assay kit. In our study, we showed that the serum level of HMGB1, whether 149.9 pg/ml or not is important in differential diagnosis between patient and control group.
SiegelR, NaishadhamD, JemalA. Cancer statistics, CA Cancer J Clin2013; 63: 1-30.
2.
BehrensG, LeitzmannMF. The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer. 2013 Mar 5; 108(4): 798-811.
3.
HengDY, XieW, ReganMM, WarrenMA, GolshayanAR, SahiC, EiglBJ, RuetherJD, ChengT, NorthS, VennerP, KnoxJJ, ChiKN, KollmannsbergerC, McDermottDF, OhWK, AtkinsMB, BukowskiRM, RiniBI, ChoueiriTK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1; 27(34): 5794-9.
4.
FerrariS, FinelliP, RocchiM, BianchiME. The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics. 1996 Jul 15; 35(2): 367-71.
5.
KornblitB, Munthe-FogL, PetersenSL, MadsenHO, VindeløvL, GarredP. The genetic variation of the human HMGB1 gene. Tissue Antigens. 2007 Aug; 70(2): 151-6.
6.
ZhangJ, McCauleyMJ, Maher, 3rdLJ, WilliamsMC, IsraeloffNE. Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res. 2009 Mar; 37(4): 1107-14.
7.
KangHJ, LeeH, ChoiHJ, YounJH, ShinJS, AhnYH, et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest. 2009; 89: 948-59.
8.
WangH, YangH, TraceyKJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004 Mar; 255(3): 320-31.
MotzerRJ, HutsonTE, TomczakP, MichaelsonMD, BukowskiRM, RixeO, OudardS, NegrierS, SzczylikC, KimST, ChenI, BycottPW, BaumCM, FiglinRA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356(2): 115-24.
11.
ScaffidiP, MisteliT, BianchiME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002 Jul 11;418(6894):191-5. Erratum in: Nature. 2010 Sep 30; 467(7315): 622.
12.
LotzeMT, TraceyKJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005 Apr; 5(4): 331-42.
13.
KostovaN, ZlatevaS, UgrinovaI and PashevaE. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 2010; 337: 251-258.
14.
CourtEL, Ann SmithM, AventND, et al. DNA microarray screening of differential gene expression in bone marrow samples from AML, non-AML patients and AML cell lines. Leuk Res. 2004; 28: 743-53.
15.
SharmaA, RayR and RajeswariMR. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest. 2008; 26: 843-851.
16.
GnanasekarM, ThirugnanamS and RamaswamyK. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol. 2009; 34: 425-431.
17.
YaoX, ZhaoG, YangH, et al. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 2010; 136: 677-684.
18.
JantzenHM, AdmonA, BellSP, TjianR. Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature. 1990; 344: 830-836.
19.
TopalovaD, UgrinovaI, PashevIG, PashevaEA. HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. Int J Biochem Cell Biol. 2008; 40: 1536-1542.
20.
SürenD, YıldırımM, DemirpençeÖ, Kaya V, AlikanoǧluAS, BülbüllerN, YıldızM, SezerC. Prognostic Role of High Mobility Group Box 1 (HMGB1) Expression as a New Treatment Target in Colorectal Cancer. Med Sci Monit. 2014; 20: 530-537.
21.
YaoX, ZhaoG, YangH, et al. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 2010; 136: 677-684.
22.
ShenX, HongL, SunH, et al. The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep. 2009; 22: 535-539.
23.
WuF, ZhaoZH, DingST, WuHH, LuJJ. High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. Asian Pac J Cancer Prev. 2013; 14(10): 5789-95.
24.
TakeuchiT, SakazumeK, TonookaA, ZaitsuM, TakeshimaY, MikamiK, UekusaT. Cytosolic HMGB1 expression in human renal clear cell cancer indicates higher pathological T classifications and tumor grades. Urol J. 2013 Sep 26; 10(3): 960-5.
25.
LinL, ZhongK, SunZ, WuG, DingG. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2012 Jan; 138(1): 11-22.
26.
CohenHT, McGovernFJ. Renal-cell carcinoma. N Engl J Med. 2005 Dec 8; 353(23): 2477-90.
